Guidant, Medtronic Look To CHF Market To Offset Slowing Of Stent Growth
This article was originally published in The Gray Sheet
Executive Summary
Seeing the initial signs of declining stent prices and an uninspiring tachycardia product line-up, investors bypassed 1998's device darlings in 1999 - Medtronic and Guidant - while keeping a close eye on efforts by those companies to develop a potentially lucrative market opportunity in treating congestive heart failure (CHF) patients.